We appreciate the correspondence of Dr van Dijk on our study in CHEST,1 in which we examined lung function decline in three groups of heavy smokers classified by their baseline prebronchodilator FEV1/FVC: >70%, ≤70%, and less than the lower limit of normal. We believe that Dr van Dijk misinterpreted the outcomes reported in Table 4. As can be found in the “Materials and Methods” section,1 the decline was analyzed by multiple linear regression with the follow-up FEV1 as the dependent variable and the baseline FEV1, among others, as an independent variable. In our Table 4, the regression coefficients (β) of the significant independent variables are listed. Classically, in linear regression analysis, the independent variables are multiplied with their regression coefficient (βx), in this case, baseline FEV1 × 0.94. From this it can be easily concluded that a higher baseline FEV1 results in a lower follow-up FEV1, and not, as implied by Dr van Dijk, in preserving airflow.